Evaluation of CCR5 inhibition in breast cancer using novel, potent inhibitors

​Grant funding 2022-2024
Ministry of Education and Sciences

Goal of the study is to evaluate CCR5 antagonism in in vitro experiments with MCF-7 and MDA-MB-231 human breast cancer cell lines using CCL5 5p12 5m antagonist and CCL5 agonist.

The present study analyses the influence of chemokine C-C motif ligand 5 (CCL5) known as Regulated upon Activation, Normal T-cell Expressed, and Secreted (shortly RANTES) through binding to its corresponding receptor C-C chemokine receptor 5 (CCR5) on cancer cell proliferation, migration, and invasion. The investigation of the CCL5/CCR5 axis is becoming one of the important factors in the relationship between inflammation and cancer cell development. As CCL5 binds to CCR5, it promotes downstream signalling cascade, where it can affect the normal physiological cell signalling pathway by chronically activating it. Recent findings regarding CCL5/CCR5 interaction led us to understand the possible pathways, which could initiate and promote cancer cell development by stimulating the growth of tumor cells, the formation of metastasis, induce angiogenesis and immunosuppression. To interrupt CCL5/CCR5 interaction, Dr. Vangelista and his colleagues previously developed a CCR5 antagonist – CCL5 5p12 5m as well as CCL5 agonist. Our work aims to evaluate the effect of CCL5 5p12 5m antagonist and CCL5 agonist on cancer cell proliferation and migration potential using human breast cancer MCF-7 and MDA-MB-231 cell lines.

at least 3 (three) articles and (or) reviews in peer-reviewed scientific journals in the scientific direction of the project, included in the 1st (first), 2nd (second) and (or) 3rd (third) quartile by impact factor in the Web of Science database and (or) having a CiteScore percentile in the Scopus database of at least 50 (fifty);
- at least 1 (one) article or review in a peer-reviewed foreign or domestic journal recommended by COXON;
- or at least 2 (two) articles and (or) reviews in peer-reviewed scientific journals included in the 1st (first) and (or) 2nd (second) quartile by impact factor in the Web of Science database and (or) having a CiteScore percentile in the Scopus database of at least 65 (sixty-five);